Prematurely ended - Statement

EudraCT Number:	2008-000653-36
Full title of the study:	Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.
Sponsor-Code:	DOCE-GEM
Sponsor:	Charité – Universitätsmedizin Berlin
Principal Investigator:	Medizinische Klinik m. S. Infektiologie und Pneumologie Dr. med. Daniel Binder
Product:	DOCETAXEL, 80 mg (Taxotere EU/1/95/002/001) GEMCITABINHYDROCHLORID, 200 mg (Gemzar Zul. Nr. :52222.00.00)
Date of early termination:	2010/07/08
Statement:	The trial will be terminated because of insufficient recruiting. The planned number of recruited patients can not be achieved in an appropriate period of time. At present, there are no patients receiving any study medication The early termination occurs at a time point when only few of the planned patients were recruited. Thus, it is not possible to get reliable results/conclusions regarding primary and secondary endpoints. The trial will be terminated without a statement on the study endpoints.